Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Longitudinal, Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Coagulation Replacement Factor Products

Clinical Trial Details

This is a longitudinal, observational study of patients with Hemophilia A or B who are planning to switch to a newly approved coagulation factor replacement product, or who have recently switched factor products. The study will follow each patient for up to 1 year. Patients will be recruited at Hemophilia Treatment Centers (HTC) which are ATHN-affiliates. The primary outcome being studied is the development of inhibitor (i.e., antibodies to factor) at 1 year or 50 exposure days, whichever comes first. 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Ilene Goldberg
(212) 746-3403
igoldber@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1602017047

Status

Open to Enrollment

Age Group

Adult , Pediatric

Disease